Rucaparib Efficacious in Metastatic Castration-Resistant Prostate Cancer
FRIDAY, Feb. 17, 2023 (HealthDay News) — For patients with metastatic castration-resistant prostate cancer, treatment with rucaparib is associated with significantly longer duration of imaging-based progression-free survival compared with a control m…
Learn MoreTalazoparib + Enzalutamide Beneficial in Metastatic Prostate Cancer
FRIDAY, Feb. 17, 2023 (HealthDay News) — For patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according to a study presented at t…
Learn MorePlant-Based Diet Linked to Reduced Risk for Prostate Cancer Progression
THURSDAY, Feb. 16, 2023 (HealthDay News) — Plant-based diets are associated with a reduced risk for prostate cancer (PC) progression and recurrence, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Canc…
Learn MoreSwitch to Plant-Based Diet Could Boost Prostate Cancer Survival
THURSDAY, Feb. 16, 2023 (HealthDay News) — Following a healthy plant-based diet after a diagnosis of prostate cancer may help prevent the disease from progressing or recurring, a new study suggests. Men who ate a diet rich in fruits, vegetables and w…
Learn MorePatient-Reported Outcome Measure Developed for Radionuclide Therapy in Prostate Cancer
MONDAY, Feb. 6, 2023 (HealthDay News) — The Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) patient-reported outcome (PRO) tool has been developed for measuring symptoms/toxicities among prostate cancer (PC) patients receiving…
Learn MoreMRI-Guided Radiotherapy Bests CT Guidance for Prostate Cancer
WEDNESDAY, Jan. 18, 2023 (HealthDay News) — Magnetic resonance imaging (MRI)-guided radiotherapy offers significant benefit over computed tomography (CT)-guided therapy for treatment of prostate cancer, according to a study published online Jan. 12 i…
Learn MoreApalutamide Safe for Men With Prostate Cancer on Active Surveillance
WEDNESDAY, Jan. 18, 2023 (HealthDay News) — For men with low- to intermediate-risk prostate cancer on active surveillance, the negative repeat biopsy rate is high following 90 days of apalutamide, according to a study published in the February issue …
Learn MoreSocial Determinants of Health Affect Racial Disparity in Prostate Cancer Mortality
FRIDAY, Jan. 13, 2023 (HealthDay News) — When accounting for social determinants of health (SDOH), Black men with prostate cancer have lower prostate cancer-specific mortality (PCSM) than White men, according to a systematic review and meta-analysis …
Learn MoreU.S. Cancer Deaths Decline Overall, But Prostate Cancers Make Rebound
THURSDAY, Jan. 12, 2023 (HealthDay News) — Cancer deaths continue to decline, dropping 33% since 1991 and saving an estimated 3.8 million lives, according to the American Cancer Society’s annual statistics report.But individual trends within that ove…
Learn MoreLow-Value Prostate Cancer Screening Common in Primary Care
TUESDAY, Jan. 10, 2023 (HealthDay News) — Low-value prostate cancer screening is common in primary care, according to a study published in the January issue of the Journal of the American Board of Family Medicine.Chris Gillette, Ph.D., from the Wake …
Learn More